AQST May 2024 4.000 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.1500 |
| Ask | 0.2500 |
| Strike | 4.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.1000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.23k |
ZacksCarisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksAnalysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE)
